-
Company Insights
Innovation and Patenting activity of Cambium Networks Corp Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Cambium Networks Corp Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
Keratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2023
Global Markets Direct’s, ‘Keratoconjunctivitis Sicca (Dry Eye) - Drugs In Development, 2023’, provides an overview of the Keratoconjunctivitis Sicca (Dry Eye) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis Sicca (Dry Eye), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Keratoconjunctivitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Keratoconjunctivitis - Drugs In Development, 2023’, provides an overview of the Keratoconjunctivitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Elate Ocular in Keratoconjunctivitis Sicca (Dry Eye)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Elate Ocular in Keratoconjunctivitis Sicca (Dry Eye) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Elate Ocular in Keratoconjunctivitis Sicca (Dry Eye) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bucindolol Hydrochloride in Atrial Fibrillation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bucindolol Hydrochloride in Atrial Fibrillation report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Bucindolol Hydrochloride in Atrial Fibrillation Drug Details:Bucindolol hydrochloride (Gencaro) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Nivolumab + Relatlimab) in Metastatic Hepatocellular Carcinoma (HCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Nivolumab + Relatlimab) in Metastatic Hepatocellular Carcinoma (HCC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.(Nivolumab + Relatlimab) in Metastatic Hepatocellular Carcinoma (HCC) Drug...
-
Company Profile
Cambium Networks Corp – Company Profile
Cambium Networks Corp (Cambium Networks) is a wireless broadband solution provider. The company offers scalable and secure WiFi, fixed wireless broadband point-to-point (PTP), industrial IoT, video surveillance, accessories and point-to-multipoint (PMP) platforms. It provides connectivity solution products such as backhaul, access, WiFi products and other software tools. Cambium Networks caters to service providers, enterprises, governmental and military agencies, oil, gas and utility companies, internet service providers and public safety networks. The company offers WiFi solutions for home, small business and...
Add to Basket -
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Elate Ocular
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry Elate Ocular Drug Details Elate ocular is under development for the treatment of keratoconjunctivitis...
-
Product Insights
Keratoconjunctivitis sicca (Dry Eye) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Keratoconjunctivitis sicca (KCS) or dry eye disease (DED) or dry eye syndrome (DES) symptoms include hyperemia, mucoid discharge, ocular irritation, photophobia, and blurry vision. Risk factors include age, wearing contact lenses and low levels of vitamin A. Treatment includes artificial tear substitutes, topical anti-inflammatory agents, secretagogues, and immunosuppressants. The KCS pipeline drugs market research report provides an analysis of the KCS drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The...
-
Analyst Opinions
5G Commercial Use Cases Update & Telco Go-To-Market Strategies
”5G Commercial Use Cases Update & Telco Go-To-Market Strategies”, a global outlook report by GlobalData, provides a status update on commercially-deployed 5G use cases globally, focusing on 5G FWA and 5G eMBB. It also outlines the go-to-market strategies that telcos have adopted for their commercial 5G offers in terms of available plans, pricing, bundling and positioning. Furthermore, it offers an overview of the 5G devices made available by telcos at launch and analyses their bundling & pricing strategies. Commercial 5G...